Making Asset Acquisition Frictionless Via Digital Marketplace and AI
Executive Summary
Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.
As biopharma companies look to bolster their pipelines, finding a promising asset takes time and meticulous due diligence. An Israeli start-up, 9xchange, is trying to take some of the friction out of the acquisition process through a digital marketplace where buyers are matched with sellers, and vice versa: a dating app for the biopharma industry.
In this episode of the In Vivo podcast, 9xchange CEO Anat Naschitz talks about the spark that led her to found the company, how it operates and the importance of "liberating and democratizing" sophisticated technologies.
Joining for the podcast is Matthew Fujisawa, SVP, strategy and corporate development at BenevolentAI Limited, to talk about the company's involvement in the 9xchange marketplace, how BenevolentAI is applying its AI tools to identify opportunities for drug repurposing and indication expansion and how the partnership represents an expansion of BenevolentAI's business and growth strategy.
Timestamps:
0:00 Intro
1:30 Anat Naschitz, CEO of 9xchange, on her journey and founding the company
3:30 Matthew Fujisawa, SVP, strategy and corporate development, BenevolentAI on his background and the BenevolentAI platforms
6:00 How 9exchange addresses deficiencies in the asset acquisition process
9:00 How BenevolentAI is leveraging its technologies to identify drug repurposing and indication expansion opportunities on 9xchange
12:50 9xchange participants, successes and business model
16:00 BenevolentAI's revised strategic plan and AI in drug R&D
19:00 On"liberating and democratizing AI"